Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Other
Gensight Biologics SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Other
-€366k
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other
-€18.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other
-€260k
|
CAGR 3-Years
60%
|
CAGR 5-Years
47%
|
CAGR 10-Years
-7%
|
|
|
Inventiva SA
PAR:IVA
|
Other
€5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other
-€2.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Other?
Other
-366k
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Other amounts to -366k EUR.
What is Gensight Biologics SA's Other growth rate?
Other CAGR 3Y
32%
Over the last year, the Other growth was 77%. The average annual Other growth rates for Gensight Biologics SA have been 32% over the past three years .
You don't have any saved screeners yet